

14 February 2024

Treatment of Specified Products for Cancer Conditions

1) In the past 6 months, how many patients were treated with a combination of both Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:

- *A) Metastatic Melanoma: 30
- B) Colorectal Cancer: <5
- C) Any other indications: <5

2) In the past 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:

- *A) Metastatic Melanoma: 18
- *B) Adjuvant Melanoma: 18
- C) BRAF mutated Lung Cancer: <5

*Please note that the responses regarding melanoma are for all melanoma patients, as metastatic, adjuvant etc are not specified on the treatment regimens

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.